He received one cycle of 6.5 GBq [161Tb]Tb-PSMA-617, and after four weeks, a partial remission was documented with a notable decrease in plasma tumor marker (prostate-specific antigen, PSA) and tumor burden which was visualized with PET/CT imaging 97. This evidence concerns the gene FOLH1 and neoplasm.